| 0.4963 0.005 (1.08%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.62 | 1-year : | 0.7 |
| Resists | First : | 0.53 | Second : | 0.6 |
| Pivot price | 0.48  |
|||
| Supports | First : | 0.42 | Second : | 0.35 |
| MAs | MA(5) : | 0.48 |
MA(20) : | 0.48  |
| MA(100) : | 0.62 |
MA(250) : | 8.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.6 |
D(3) : | 60.2 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 68.4 | Low : | 0.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AZTR ] has closed below upper band by 39.8%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 84 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.51 | 0.51 - 0.51 |
| Low: | 0.47 - 0.47 | 0.47 - 0.48 |
| Close: | 0.49 - 0.5 | 0.5 - 0.5 |
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Thu, 14 Nov 2024
Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com
Tue, 12 Nov 2024
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire
Tue, 29 Oct 2024
Azitra to Present at BIO-Europe 2024 | AZTR Stock News - StockTitan
Fri, 11 Oct 2024
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Business Wire
Tue, 08 Oct 2024
Azitra stock plunges to 52-week low, hits $0.49 - Investing.com
Tue, 24 Sep 2024
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 6.83e+006 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 311 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.012e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | 470.3 % |
| Return on Equity (ttm) | -93.5 % |
| Qtrly Rev. Growth | 408200 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 92.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 9.58 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 208380 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|